Literature DB >> 20813343

Alzheimer's disease, a multifactorial disorder seeking multitherapies.

Khalid Iqbal1, Inge Grundke-Iqbal.   

Abstract

Alzheimer's disease (AD) is multifactorial and apparently involves several different etiopathogenic mechanisms. There are at least five subgroups of AD based on cerebrospinal fluid levels of Abeta(1-42), a marker of beta-amyloid (Abeta) plaques, and tau and ubiquitin, two markers of neurofibrillary tangles. These different AD subgroups may respond differently to a given disease-modifying drug, and hence, different therapeutic drugs for different disease subgroups might be required. Stratification of AD patients by disease subgroups in clinical trials is critical to the successful development of potent disease-modifying drugs. Levels of disease markers in the cerebrospinal fluid are promising, both in identifying various subgroups of AD and in monitoring the response to therapeutic drugs. Copyright 2010 The Alzheimer

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813343      PMCID: PMC2946155          DOI: 10.1016/j.jalz.2010.04.006

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  38 in total

1.  Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations.

Authors:  M Arrasate; M Pérez; R Armas-Portela; J Avila
Journal:  FEBS Lett       Date:  1999-03-05       Impact factor: 4.124

2.  Promotion of hyperphosphorylation by frontotemporal dementia tau mutations.

Authors:  Alejandra del C Alonso; Anna Mederlyova; Michal Novak; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Biol Chem       Date:  2004-06-09       Impact factor: 5.157

3.  Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease.

Authors:  José Luna-Muñoz; Francisco García-Sierra; Viviana Falcón; Ivón Menéndez; Laura Chávez-Macías; Raúl Mena
Journal:  J Alzheimers Dis       Date:  2005-09       Impact factor: 4.472

Review 4.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

5.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

Authors:  I Grundke-Iqbal; K Iqbal; Y C Tung; M Quinlan; H M Wisniewski; L I Binder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Neurons may live for decades with neurofibrillary tangles.

Authors:  R Morsch; W Simon; P D Coleman
Journal:  J Neuropathol Exp Neurol       Date:  1999-02       Impact factor: 3.685

7.  Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease.

Authors:  K A Jellinger; J Attems
Journal:  Acta Neuropathol       Date:  2006-11-07       Impact factor: 17.088

Review 8.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.

Authors:  R Katzman; R Terry; R DeTeresa; T Brown; P Davies; P Fuld; X Renbing; A Peck
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

View more
  63 in total

1.  A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and H2O2-Induced Cytotoxicity in SH-SY5Y Cells.

Authors:  Chen Cheng; Nan Zheng; Deyang Sun; Weishuo Fang; Lingling Zheng; Weihong Song; Jian Huang
Journal:  Neurochem Res       Date:  2020-06-18       Impact factor: 3.996

2.  Dysfunction of GABAergic neurons in the parafacial zone mediates sleep disturbances in a streptozotocin-induced rat model of sporadic Alzheimer's disease.

Authors:  Jin-Zhi Song; Su-Ying Cui; Xiang-Yu Cui; Xiao Hu; Yu-Nu Ma; Hui Ding; Hui Ye; Yong-He Zhang
Journal:  Metab Brain Dis       Date:  2017-10-28       Impact factor: 3.584

3.  Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.

Authors:  Yang Yu; Xiaojing Li; Julie Blanchard; Yi Li; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  J Neural Transm (Vienna)       Date:  2014-08-13       Impact factor: 3.575

4.  Pathological Alterations of Tau in Alzheimer's Disease and 3xTg-AD Mouse Brains.

Authors:  Longfei Li; Yanli Jiang; Wen Hu; Yunn Chyn Tung; Chunling Dai; Dandan Chu; Cheng-Xin Gong; Khalid Iqbal; Fei Liu
Journal:  Mol Neurobiol       Date:  2019-02-08       Impact factor: 5.590

Review 5.  Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Biochem Pharmacol       Date:  2014-01-10       Impact factor: 5.858

Review 6.  Noncoding RNAs in Alzheimer's disease.

Authors:  M Laura Idda; Rachel Munk; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-01-12       Impact factor: 9.957

Review 7.  Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.

Authors:  Paul J Derry; Muralidhar L Hegde; George R Jackson; Rakez Kayed; James M Tour; Ah-Lim Tsai; Thomas A Kent
Journal:  Prog Neurobiol       Date:  2019-10-08       Impact factor: 11.685

8.  Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation.

Authors:  Pradeep K Singh; Masanori Kawasaki; Hanna E Berk-Rauch; Goushi Nishida; Takeshi Yamasaki; Michael A Foley; Erin H Norris; Sidney Strickland; Kazuyoshi Aso; Hyung Jin Ahn
Journal:  Biochemistry       Date:  2018-02-09       Impact factor: 3.162

9.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

10.  A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse).

Authors:  Yanxing Chen; Zhihou Liang; Julie Blanchard; Chun-Ling Dai; Shenggang Sun; Moon H Lee; Inge Grundke-Iqbal; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2012-11-14       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.